OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD ), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that Rick Altieri, Chief Financial Officer, will present at the Baird 2016 Global Healthcare Conference on Wednesday, September 7, 2016, at 2:35 p.m. ET at the New York Palace in New York, NY.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The Company's first product is the T-SPOT ® . TB test, which is used to test for tuberculosis infection. The T-SPOT. TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The T-SPOT. CMV test and the T-SPOT. PRT test are the Company's second and third products and part of a series of products intended for the transplantation market. In addition to these three products, the Company has an additional six active development programs, each of which leverages our T cell, B cell and innate immune measuring technology. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com .
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
CONTACTS:
For Media Inquiries: Caroline Crawley Oxford Immunotec Tel: +44 1235 442796 ccrawley@oxfordimmunotec.com
For Investor Inquiries: Rick Altieri Chief Financial Officer Oxford Immunotec Tel: +1 (508) 573-9953 raltieri@oxfordimmunotec.com
Mark Klausner Westwicke Partners Tel: +1 (443) 213-0501 oxfordimmunotec@westwicke.com